on the way to $1, page-25

Hi Thanky,

Two things stand out to me that may have contributed.

Point 4: "This result may be related to the stability or performance properties of the specific batch of commercially sourced assay kits"
and
Point 5: "...In-house development ... expected to reduce the risks of unreliable supply and test performance variability associated with commercially available assay kits"

IMO I read this as they are not satisfied with the quality and reliability of externally sourced assay kits, they believe this may have adversely affected the study, however by developing antibodies and reagents in-house they may be able to reduce performance risks associated with external assay kits.

Just a thought, happy to be corrected.